Welcure Secures Rs 85.6 Cr Export Orders, Strengthens Global Play

Welcure Drugs & Pharmaceuticals announced two significant export sourcing orders worth Rs 85.6 crore, signaling yet another step toward global pharmaceutical sourcing solutions.

The dual sets of contracts were from Thailand-based clients (Giant Exim and Ravina International) and are both worth Rs 42.8 crore for the procurement and consolidation of mycorrhizal inoculants, all on EXW terms. Welcure was able to reduce its inventory and logistics risks while still being able to generate margin-rich fees.

These sourcing orders continue the spirit of Welcure's broader change in direction to a commission-based, asset-light business model. As an example, the company was able to earn fees on dispatchs rather than hold working capital which enhances profitability and manageability. The announcement of these orders follows a previous sourcing order for Rs 517 crore withThailand's Fortune Sagar Impex signed only weeks earlier.

Also Read: Fetal Imaging to Cardiac Diagnosis: The Expanding Role of Ultrasound

The most recent sourcing order has helped to further support the marketplace with Welcure stock increasing almost 5% on the BSE to Rs 13.60. This reflects analysts and investor renewed confidence and increasing appetite for Indian pharma sourcing capabilities especially for global edge offerings in niche areas like agri-biologicals.

With additional export discussions worth over Rs 20 crore underway, Welcure is well-positioned to scale its global sourcing footprint and reinforce India’s strength in the pharmaceutical export space.